Trial Information
Current as of March 14, 2025
Not yet recruiting
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Rutherford clinical category 4-6 of the target limb
- • Age of subjects is \>18 years old
- • Patients has given informed consent to participate in this study
- Exclusion Criteria:
- • De novo or restenotic (without prior stent) stenosis (≥70%) or occlusion
- • Target lesion is in the BTK arteries, including below the knee popliteal, tibioperoneal trunk, tibial, peroneal, and pedal arteries.
- • Angiographic visual estimated reference vessel diameter is between 2.0 and 5.0 mm.
- • Lesion length less than 220 mm
About Cagent Vascular Llc
Cagent Vascular LLC is a pioneering medical device company focused on advancing vascular health through innovative solutions. Specializing in the development and commercialization of cutting-edge technologies for the treatment of peripheral artery disease, Cagent Vascular is committed to enhancing patient outcomes and improving overall quality of care. The company emphasizes rigorous clinical research and collaboration with healthcare professionals to ensure the efficacy and safety of its products, positioning itself as a leader in the field of vascular interventions. With a dedication to excellence and a patient-centered approach, Cagent Vascular is at the forefront of transforming vascular care.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Related articles
